- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
The changing dynamics of the life sciences landscape
13 December 2016 • Author(s): Noel Gaule, Shire
The life sciences industry is dynamic and as we move towards 2020 and beyond, associated technologies will continue to converge. The forthcoming political, socio-economic and scientific era will throw up challenges, however, with these challenges will come great opportunities. As times change, pharmaceutical companies will need to employ innovative strategies for success. Importantly, patients will always be at the heart of the life sciences sector and as the gap between the world’s rich and poor grows, governments will increasingly have to develop ways to partner with the industry in order to make medicinal products as widely available as possible. For pharma, close collaboration with advocacy groups, governments, regulators and investors will be vital for ensuring success.
That success is imminent: by 2020 the pharmaceutical market is anticipated to be worth more than $1.3 trillion, a figure that is arguably unsurprising given the rising incidence of diseases and ageing populations. One major trend is that the incidence of chronic conditions in the developing world is increasingly matching the patterns seen in the developed world. For example, in 2004 an estimated 639 million people living in developing countries suffered from hypertension. In 2025 the number is forecast to reach at least one billion – more than twice the projected rate of increase in that same population over the same timeframe. The outlook is similar when it comes to diabetes. The number of people living with this disease in emerging markets is expected to rise from 84 million in 1995 to 228 million in 2025, with India, the Middle East and South East Asia bearing the worst of the burden.
The United States spends over $10,000 per year on each patient with diabetes. If India’s per capita expenditure rises to one-tenth of this level, the total cost of treating patients with this disease will be over $73.5 billion by 2025. Conversely, preventing 10% of the population from developing diabetes would save $8 billion a year.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics